title: Trabectedin: novel insights in the treatment of advanced sarcoma.
abstract: Soft tissue sarcomas are a heterogenous group of malignancies with relatively high mortality rates. The outlook for these patients has been poor, with only a few drugs showing measurable activity. Trabectedin is a new alkylating agent with significant activity in sarcomas, but particularly in liposarcomas and leiomyosarcomas, both as a single agent or in combination with other drugs. Phase I and II studies of trabectedin have shown measurable benefit. Currently there are several Phase III trials which have completed accrual to better study its use as a single agent or in combination therapy, although outcomes have not yet been reported. Trabectedin (Yondelis) is approved for the treatment of sarcomas by the EMEA, but is not yet approved by the FDA, pending the results of the currently maturing phase III trials.
authors.affiliation: Department of Medicine, University of Colorado at Denver, Denver, CO, USA.
authors.forename: Jay Patrick
authors.initials: JP
authors.lastname: Lopez
authors.forename: Csaba
authors.initials: C
authors.lastname: Gajdos
authors.forename: Anthony
authors.initials: A
authors.lastname: Elias
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004149:Dioxoles / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D000077606:Trabectedin
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin
references.citation: Ann Oncol. 1998 Sep;9(9):981-7
references.pmid: 9818072
references.citation: J Clin Oncol. 2001 Mar 1;19(5):1248-55
references.pmid: 11230465
references.citation: Cancer. 1983 Aug 1;52(3):424-34
references.pmid: 6344981
references.citation: J Clin Oncol. 2004 Apr 15;22(8):1480-90
references.pmid: 15084621
references.citation: Eur J Cancer. 2001 Jan;37(1):97-105
references.pmid: 11165136
references.citation: J Clin Oncol. 1995 Jul;13(7):1537-45
references.pmid: 7602342
references.citation: Cancer Invest. 2002;20(5-6):605-12
references.pmid: 12197215
references.citation: J Clin Oncol. 2001 Aug 1;19(15):3483-9
references.pmid: 11481354
references.citation: Chem Biol. 2001 Dec;8(12):1151-60
references.pmid: 11755394
references.citation: Anticancer Drugs. 2010 Jan;21(1):113-9
references.pmid: 19887935
references.citation: J Clin Oncol. 2005 Jan 20;23(3):576-84
references.pmid: 15659504
references.citation: Br J Cancer. 1996 Apr;73(8):875-83
references.pmid: 8611420
references.citation: Oncologist. 2012;17(9):1213-20
references.pmid: 22907974
references.citation: Clin Cancer Res. 2010 May 1;16(9):2656-65
references.pmid: 20406837
references.citation: Eur J Cancer. 2009 May;45(7):1153-1161
references.pmid: 19114300
references.citation: Cancer. 1994 Mar 15;73(6):1652-9
references.pmid: 8156492
references.citation: J Clin Oncol. 1998 Jan;16(1):197-203
references.pmid: 9440743
references.citation: Cancer. 1982 Dec 15;50(12):2757-62
references.pmid: 7139566
references.citation: Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):1003-9
references.pmid: 22560550
references.citation: Oncologist. 2005 Nov-Dec;10(10):827-32
references.pmid: 16314293
references.citation: J Oncol Pharm Pract. 2014 Aug;20(4):288-97
references.pmid: 24022407
references.citation: J Clin Oncol. 2005 Aug 20;23(24):5484-92
references.pmid: 16110008
references.citation: Clin Cancer Res. 2008 Oct 15;14(20):6656-62
references.pmid: 18927308
references.citation: Clin Cancer Res. 2001 Jan;7(1):185-91
references.pmid: 11205907
references.citation: Clin Cancer Res. 2001 Sep;7(9):2908-11
references.pmid: 11555609
references.citation: Invest New Drugs. 2012 Apr;30(2):616-28
references.pmid: 20927639
references.citation: Cancer Chemother Pharmacol. 2008 Dec;63(1):181-8
references.pmid: 18379785
references.citation: Ann Oncol. 1999 Oct;10(10):1233-40
references.pmid: 10586342
references.citation: Ann Oncol. 2010 Oct;21 Suppl 7:vii270-6
references.pmid: 20943627
references.citation: J Biol Chem. 2002 Nov 1;277(44):41580-9
references.pmid: 12198119
references.citation: Biochemistry. 1996 Oct 15;35(41):13303-9
references.pmid: 8873596
references.citation: Clin Oncol (R Coll Radiol). 2007 Oct;19(8):572-6
references.pmid: 17624747
references.citation: Ann Oncol. 2013 Jun;24(6):1703-9
references.pmid: 23385197
references.citation: J Clin Oncol. 1987 Jun;5(6):840-50
references.pmid: 3585441
references.citation: Int J Cancer. 2001 May 15;92(4):583-8
references.pmid: 11304695
references.citation: Ann Oncol. 2012 Oct;23(10):2763-2770
references.pmid: 22492696
references.citation: Eur J Cancer. 2012 Mar;48(4):579-85
references.pmid: 22088484